{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:38:27Z","timestamp":1792669107401,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12325-019-00971-0","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T09:15:39Z","timestamp":1558084539000},"page":"1532-1548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview"],"prefix":"10.1007","volume":"36","author":[{"given":"Theodoros","family":"Empeslidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassileios","family":"Konidaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paris G.","family":"Tranos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia S.","family":"Panagiotou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irini C.","family":"Voudouragkaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios G.","family":"Konstas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"issue":"15","key":"971_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","volume":"291","author":"N Bressler","year":"2004","unstructured":"Bressler N. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900\u20131.","journal-title":"JAMA"},{"issue":"4","key":"971_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.1941.00870100042005","volume":"122","author":"D Friedman","year":"2004","unstructured":"Friedman D, O\u2019Colmain B, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564\u201372.","journal-title":"Arch Ophthalmol"},{"issue":"9827","key":"971_CR3","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728\u201338.","journal-title":"Lancet"},{"key":"971_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"P Rosenfeld","year":"2006","unstructured":"Rosenfeld P, Brown D, Heier J, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"971_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"335","author":"D Brown","year":"2006","unstructured":"Brown D, Kaiser P, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;335:1432\u201344.","journal-title":"N Engl J Med"},{"key":"971_CR6","first-page":"CD005139","volume":"2","author":"SS Vedula","year":"2008","unstructured":"Vedula SS, Krzystolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008;2:CD005139.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"971_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","volume":"118","author":"PJ Rosenfeld","year":"2011","unstructured":"Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2\u00a0years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118(3):523\u201330.","journal-title":"Ophthalmology"},{"issue":"7","key":"971_CR8","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results: comparison of age-related macular degeneration treatments trials research group. Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"key":"971_CR9","first-page":"9640131","volume":"2018","author":"X Zhang","year":"2018","unstructured":"Zhang X, Lai TYY. Baseline predictors of visual acuity outcome in patients with wet age-related macular degeneration. Biomed Res Int. 2018;2018:9640131.","journal-title":"Biomed Res Int"},{"issue":"3","key":"971_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40291-018-0332-1","volume":"22","author":"L Lores-Motta","year":"2018","unstructured":"Lores-Motta L, de Jong EK, den Hollander AI. Exploring the use of molecular biomarkers for precision medicine in age-related macular degeneration. Mol Diagn Ther. 2018;22(3):315\u201343.","journal-title":"Mol Diagn Ther"},{"key":"971_CR11","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1001\/archopht.124.12.1754","volume":"124","author":"D Rein","year":"2006","unstructured":"Rein D, Zhang P, Wirth K, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124:1754\u201360.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"971_CR12","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1055\/s-0033-1351029","volume":"230","author":"S Husler","year":"2013","unstructured":"Husler S, Schmid H. Coping with wet age-related macular degeneration: a study from Switzerland. Klin Monbl Augenheilkd. 2013;230(12):1251\u20136.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"3","key":"971_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/bjo.2005.080986","volume":"90","author":"HR Taylor","year":"2006","unstructured":"Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol. 2006;90(3):272\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"971_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jfma.2011.09.021","volume":"111","author":"JC Lin","year":"2012","unstructured":"Lin JC, Yu JH. Assessment of quality of life among Taiwanese patients with visual impairment. J Formos Med Assoc. 2012;111(10):572\u20139.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"971_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archopht.118.1.47","volume":"118","author":"G Brown","year":"2000","unstructured":"Brown G, Sharma S, Brown M, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol. 2000;118(1):47\u201351.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"971_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","volume":"117","author":"NM Bressler","year":"2010","unstructured":"Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010;117(4):747\u201356.","journal-title":"Ophthalmology"},{"key":"971_CR17","doi-asserted-by":"publisher","first-page":"830837","DOI":"10.1155\/2013\/830837","volume":"2013","author":"M Hanout","year":"2013","unstructured":"Hanout M, Ferraz D, Ansari M, et al. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. Biomed Res Int. 2013;2013:830837.","journal-title":"Biomed Res Int"},{"issue":"1","key":"971_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193\u2013201.","journal-title":"Ophthalmology"},{"issue":"6","key":"971_CR19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/eye.2017.7","volume":"31","author":"L Tiosano","year":"2017","unstructured":"Tiosano L, Segal O, Mathalone N, et al. Aflibercept as a second line therapy for neovascular age related macular degeneration in Israel (ASLI) study. Eye (Lond). 2017;31(6):890\u20138.","journal-title":"Eye (Lond)"},{"issue":"5","key":"971_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.5301\/ejo.5000757","volume":"26","author":"KA Aghdam","year":"2016","unstructured":"Aghdam KA, Pielen A, Framme C, Junker B. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results. Eur J Ophthalmol. 2016;26(5):473\u20138.","journal-title":"Eur J Ophthalmol"},{"issue":"9","key":"971_CR21","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00417-014-2838-5","volume":"253","author":"Y Kawashima","year":"2014","unstructured":"Kawashima Y, Oishi A, Tsujikawa A, et al. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2014;253(9):1471\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"971_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000440886","volume":"55","author":"AA Chang","year":"2015","unstructured":"Chang AA, Broadhead GK, Hong T, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomes. Ophthalmic Res. 2015;55(2):84\u201390.","journal-title":"Ophthalmic Res"},{"key":"971_CR23","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/OPTH.S87043","volume":"9","author":"RP Singh","year":"2015","unstructured":"Singh RP, Srivastava SK, Ehlers JP, et al. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. Clin Ophthalmol. 2015;9:1759\u201366.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"971_CR24","first-page":"481","volume":"6","author":"B Curry","year":"2017","unstructured":"Curry B, Bylsma G, Hewitt AW, Verma N. The VEGF treatment of AMD switch study (The vTAS Study). Asia Pac J Ophthalmol (Phila). 2017;6(6):481\u20137.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"971_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000001928","volume":"00","author":"R Blanco-Garavito","year":"2017","unstructured":"Blanco-Garavito R, Jung C, Uzzan J, et al. Aflibercept after ranibiumab intravitreal injections in exudative age-related macular degeneration: the ARI2 Study. Retina. 2017;00:1\u20138.","journal-title":"Retina"},{"issue":"3","key":"971_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00417-016-3477-9","volume":"255","author":"M Zhu","year":"2017","unstructured":"Zhu M, Wijeyakumar W, Syed AR, et al. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255(3):475\u201384.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"971_CR27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bjophthalmol-2013-304736","volume":"98","author":"CC Wykoff","year":"2014","unstructured":"Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014;98(7):951\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"971_CR28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/eye.2014.101","volume":"28","author":"DS Grewal","year":"2014","unstructured":"Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond). 2014;28(7):895\u20139.","journal-title":"Eye (Lond)"},{"key":"971_CR29","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/IAE.0000000000000751","volume":"36","author":"V Sarao","year":"2016","unstructured":"Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P. Intravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibiumab therapy. Retina. 2016;36:770\u20137.","journal-title":"Retina"},{"issue":"4","key":"971_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.sjopt.2016.10.008","volume":"30","author":"A Sleiman","year":"2016","unstructured":"Sleiman A. Aflibercept in refractory wet AMD treated with ranibizumab: anatomical and visual outcome. Saudi J Ophthalmol. 2016;30(4):227\u201332.","journal-title":"Saudi J Ophthalmol"},{"key":"971_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000001876","volume":"1","author":"K Kim","year":"2017","unstructured":"Kim K, Kim E, Kim Y, Yang J, Yu S, Kwak H. Outcome of intravitreal aflibercept for refractory pigment epithelial detachment with or without subretinal fluid and secondary to age-related macular degeneration. Retina. 2017;1:1\u201311.","journal-title":"Retina"},{"key":"971_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/IAE.0000000000000664","volume":"6","author":"I Mantel","year":"2016","unstructured":"Mantel I, Gianniou C, Dirani A. Conversion to aflibercept therapy versus continuing with ranibizumab therapy for neovascular age-related macular degeneration dependent on monthly ranibizumab treatment. Retina. 2016;6:53\u20138.","journal-title":"Retina"},{"issue":"5","key":"971_CR33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/aos.13480","volume":"95","author":"OK Jorstad","year":"2017","unstructured":"Jorstad OK, Faber RT, Moe MC. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Acta Ophthalmol. 2017;95(5):460\u20133.","journal-title":"Acta Ophthalmol"},{"key":"971_CR34","first-page":"160","volume":"112","author":"C Chan","year":"2014","unstructured":"Chan C, Jain A, Sadda S, Varshney N. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthlmological Society thesis). Trans Am Ophthalmol Soc. 2014;112:160\u201398.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"971_CR35","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","volume":"33","author":"N Kumar","year":"2013","unstructured":"Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranbizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33:1605\u201312.","journal-title":"Retina"},{"key":"971_CR36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2147\/OPTH.S101596","volume":"10","author":"T Hirakata","year":"2016","unstructured":"Hirakata T, Fujinami K, Watanabe K, Sasaki M, Noda T, Akiyama K. One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement. Clin Ophthalmol. 2016;10:969\u201377.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"971_CR37","first-page":"1156","volume":"9","author":"AN Warwick","year":"2016","unstructured":"Warwick AN, Leaver HH, Lotery AJ, Goverdhan SV. Fixed bimonthly aflibercept in naive and switched neovascular age-related macular degeneration patients: 1\u00a0year outcomes. Int J Ophthalmol. 2016;9(8):1156\u201362.","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"971_CR38","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10792-016-0294-4","volume":"37","author":"I Kocak","year":"2017","unstructured":"Kocak I. Intravitreal aflibercept in treatment-resistant pigment epithelial detachment. Int Ophthalmol. 2017;37(3):531\u20137.","journal-title":"Int Ophthalmol"},{"issue":"11","key":"971_CR39","doi-asserted-by":"publisher","first-page":"832","DOI":"10.4103\/0301-4738.171964","volume":"63","author":"DS Narayan","year":"2015","unstructured":"Narayan DS, Muecke J. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab. Indian J Ophthalmol. 2015;63(11):832\u20136.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"971_CR40","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/bjophthalmol-2013-303344","volume":"97","author":"H Cho","year":"2013","unstructured":"Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and\/or bevacizumab. Br J Ophthalmol. 2013;97(8):1032\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"971_CR41","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3928\/23258160-20141118-07","volume":"45","author":"MR Thorell","year":"2014","unstructured":"Thorell MR, Nunes RP, Chen GW, et al. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD. Ophthalmic Surg Lasers Imaging Retina. 2014;45(6):526\u201333.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"971_CR42","doi-asserted-by":"publisher","first-page":"273754","DOI":"10.1155\/2014\/273754","volume":"2014","author":"M Gharbiya","year":"2014","unstructured":"Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int. 2014;2014:273754.","journal-title":"Biomed Res Int"},{"issue":"4","key":"971_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1089\/jop.2013.0188","volume":"30","author":"LB Hall","year":"2014","unstructured":"Hall LB, Zebardast N, Huang JJ, Adelman RA. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients. J Ocul Pharmacol Ther. 2014;30(4):346\u201352.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9","key":"971_CR44","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/bjophthalmol-2013-304829","volume":"98","author":"WB Messenger","year":"2014","unstructured":"Messenger WB, Campbell JP, Faridi A, et al. Injection frequency and anatomic outcomes 1\u00a0year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2014;98(9):1205\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"3\u20134","key":"971_CR45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000381221","volume":"233","author":"J Pinheiro-Costa","year":"2015","unstructured":"Pinheiro-Costa J, Costa JM, Beato JN, et al. Switch to aflibercept in the treatment of neovascular AMD: one-year results in clinical practice. Ophthalmologica. 2015;233(3\u20134):155\u201361.","journal-title":"Ophthalmologica"},{"issue":"3","key":"971_CR46","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ajo.2014.11.022","volume":"159","author":"CA Arcinue","year":"2015","unstructured":"Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(3):426\u201336.","journal-title":"Am J Ophthalmol"},{"key":"971_CR47","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1097\/IAE.0000000000000813","volume":"36","author":"S De Massougnes","year":"2016","unstructured":"De Massougnes S, Dirani A, Ambresin A, Delugis D, Marchionno L, Mantel I. Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab. Retina. 2016;36:881\u20138.","journal-title":"Retina"},{"key":"971_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.03.038","volume":"167","author":"IK Muftuoglu","year":"2016","unstructured":"Muftuoglu IK, Arcinue CA, Tsai FF, et al. Long-term results of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration. Am J Ophthalmol. 2016;167:1\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"971_CR49","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/eye.2016.95","volume":"30","author":"F Ricci","year":"2016","unstructured":"Ricci F, Parravano M, Regine F, et al. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. Eye (Lond). 2016;30(8):1077\u201383.","journal-title":"Eye (Lond)"},{"issue":"3","key":"971_CR50","doi-asserted-by":"publisher","first-page":"342","DOI":"10.5301\/ejo.5000861","volume":"27","author":"L Van Lancker","year":"2017","unstructured":"Van Lancker L, Petrarca R, Moutsouris K, Masaoutis P, Kampougeris G. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization. Eur J Ophthalmol. 2017;27(3):342\u20135.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"971_CR51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12886-017-0471-x","volume":"17","author":"M Waizel","year":"2017","unstructured":"Waizel M, Todorova MG, Masyk M, et al. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. BMC Ophthalmol. 2017;17(1):79.","journal-title":"BMC Ophthalmol"},{"key":"971_CR52","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1097\/IAE.0000000000001726","volume":"38","author":"Q You","year":"2018","unstructured":"You Q, Gaber R, Meshi A, et al. High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration. Retina. 2018;38:1156\u201365.","journal-title":"Retina"},{"key":"971_CR53","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/OPTH.S160367","volume":"12","author":"A Dirani","year":"2018","unstructured":"Dirani A, Mantel I. Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance. Clin Ophthalmol. 2018;12:593\u2013600.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"971_CR54","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.ophtha.2016.05.002","volume":"123","author":"I Chatziralli","year":"2016","unstructured":"Chatziralli I, Nicholson L, Vrizidou E, et al. Predictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly aflibercept. Ophthalmology. 2016;123(8):1762\u201370.","journal-title":"Ophthalmology"},{"issue":"6","key":"971_CR55","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3928\/23258160-20150610-07","volume":"46","author":"A Kanesa-Thasan","year":"2015","unstructured":"Kanesa-Thasan A, Grewal D, Gill M, Lyon A, Mirza R. Quantification of change in pigment epithelial detachment volume and morphology after transition to intravitreal aflibercept in eyes with recalcitrant neovascular AMD: 18-month results. Ophthalmic Surg Lasers Imaging Retina. 2015;46(6):638\u201341.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"12","key":"971_CR56","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1136\/bjophthalmol-2015-308090","volume":"100","author":"D Barthelmes","year":"2016","unstructured":"Barthelmes D, Campain A, Nguyen P, et al. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol. 2016;100(12):1640\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"971_CR57","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12886-018-0824-0","volume":"18","author":"P Tyagi","year":"2018","unstructured":"Tyagi P, Juma Z, Hor YK, Scott NW, Ionean A, Santiago C. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from ranibizumab to aflibercept. BMC Ophthalmol. 2018;18(1):148.","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"971_CR58","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/eye.2015.87","volume":"29","author":"N Homer","year":"2015","unstructured":"Homer N, Grewal DS, Mirza RG, Lyon AT, Gill MK. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results. Eye (Lond). 2015;29(9):1152\u20135.","journal-title":"Eye (Lond)"},{"issue":"Suppl 1","key":"971_CR59","doi-asserted-by":"publisher","first-page":"i17","DOI":"10.1136\/bjophthalmol-2013-304474","volume":"98","author":"PJ Ferrone","year":"2014","unstructured":"Ferrone PJ, Anwar F, Naysan J, et al. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration. Br J Ophthalmol. 2014;98(Suppl 1):i17\u201321.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"971_CR60","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3341\/kjo.2015.29.4.226","volume":"29","author":"DRC Moon","year":"2015","unstructured":"Moon DRC, Lee DK, Kim SH, You YS, Kwon OW. Aflibercept treatment for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy refractory to anti-vascular endothelial growth factor. Korean J Ophthalmol. 2015;29(4):226\u201332.","journal-title":"Korean J Ophthalmol"},{"key":"971_CR61","unstructured":"Cardoso P, Pinheiro AF, Meira J, et al. Switch to aflibercept in the treatment of neovascular AMD: long-term results. J Ophthalmol. 2017;2017:6835782."},{"key":"971_CR62","first-page":"1","volume":"1","author":"C Lee","year":"2017","unstructured":"Lee C, Kim A, Baughman D, et al. Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained. Retina. 2017;1:1\u20136.","journal-title":"Retina"},{"issue":"6","key":"971_CR63","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29(6):721\u201331.","journal-title":"Eye (Lond)"},{"issue":"7","key":"971_CR64","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/lsm.22531","volume":"48","author":"K Abri Aghdam","year":"2016","unstructured":"Abri Aghdam K, Seidensticker F, Pielen A, Framme C, Junker B. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography. Lasers Surg Med. 2016;48(7):668\u201377.","journal-title":"Lasers Surg Med"},{"issue":"4","key":"971_CR65","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10384-015-0387-z","volume":"59","author":"Y Nomura","year":"2015","unstructured":"Nomura Y, Yanagi Y. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability. Jpn J Ophthalmol. 2015;59(4):261\u20135.","journal-title":"Jpn J Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00971-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T23:19:10Z","timestamp":1589584750000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00971-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["971"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00971-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"8 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}